



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333

August 26, 2022

SENT VIA EMAIL

Austin Evers
American Oversight
1030 15th Street NW
Suite B255
Washington, District of Columbia 20005
Email: foia@americanoversight.org

Dear Mr. Evers:

This letter is our final response regarding your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of March 4, 2020, assigned #20-00801-FOIA (copy of request enclosed).

We are providing 21 pages of responsive records. Included in this set of records are the records we consulted with the Office of Management and Budget (6 pages), and the records we consulted jointly with the Food and Drug Administration and the Department of Health and Human Services (15 pages). After a careful review of these pages, some information was withheld from release pursuant to 5 U.S.C. §552 Exemption (b)(4), (b5) and (b)(6).

EXEMPTION 4

Exemption 4 protects trade secrets and commercial or financial information obtained from a person that is privileged or confidential. The information withheld is commercial or financial information, such as shipping information, number of tests, invoice amount, and other activities related to private companies, and we have determined that the individuals to whom this information pertains have a substantial commercial or financial interest in withholding it.

EXEMPTION 5

Exemption 5 protects inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency. Exemption 5 therefore incorporates the privileges that protect materials from discovery in litigation, including the deliberative process, attorney work-product, and attorney-client privileges. Information withheld under this exemption was protected under the deliberative process privilege. The deliberative process privilege protects the decision-making process of government agencies. The deliberative process privilege protects materials that are both predecisional and deliberative. The materials that have been withheld under the deliberative process privilege of Exemption 5 are both predecisional and deliberative, and do not contain or represent formal or informal agency policies or decisions. Examples of information withheld include comments, recommendations, and opinions. The presidential communications privilege protects documents solicited and received by the President or his immediate White House advisers who have broad and significant responsibility for investigating and formulating the advice to be given to the President.


EXEMPTION 6

Exemption 6 protects information in personnel and medical files and similar files when disclosure would constitute a clearly unwarranted invasion of personal privacy. The information that has been withheld under Exemption 6 consists of personal information, such as email addresses and cell phone numbers. We have determined that the individuals to whom this information pertains has a substantial privacy interest in withholding it.

If you are not satisfied with the response to this request, you may administratively appeal by writing to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, Suite 729H, Washington, D.C. 20201. You may also transmit your appeal via email to FOIARequest@psc.hhs.gov.

Please mark both your appeal letter and envelope “FOIA Appeal.” Your appeal must be postmarked or electronically transmitted by November 25, 2022.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized, cursive script.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
Phone: (770) 488-6399
Fax: (404) 235-1852

Enclosures

#20-00801-FOIA

From: Giroir, Brett (HHS/OASH)
Sent: Sun, 8 Mar 2020 14:46:26 +0000
To: Schuchat, Anne MD (CDC/OD); Stenzel, Timothy (FDA/CDRH); Lenihan, Keagan (FDA/OC); Berger, Sherri (CDC/OCOO/OD)
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD); Schwartz, Suzanne (FDA/CDRH); Shuren, Jeff (FDA/CDRH); Caccomo, Stephanie (FDA/OC); Hillebrenner, Elizabeth J (FDA/CDRH); Flannery, Ellen (FDA/CDRH)
Subject: RE: update from fda and cdc

We are doing so and limiting distribution on working docs

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Sunday, March 8, 2020 10:46 AM
To: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Hillebrenner, Elizabeth J (FDA/CDRH) <Elizabeth.Hillebrenner@fda.hhs.gov>; Flannery, Ellen (FDA/CDRH) <Ellen.Flannery@fda.hhs.gov>
Subject: update from fda and cdc

Tim: It would be very helpful if you could change the subject line on your 'reply all' messages. Thank you for considering this request.

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Sunday, March 8, 2020 10:42 AM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>; Caccomo, Stephanie (FDA/OC) <Stephanie.Caccomo@fda.hhs.gov>; Hillebrenner, Elizabeth J (FDA/CDRH) <Elizabeth.Hillebrenner@fda.hhs.gov>; Flannery, Ellen (FDA/CDRH) <Ellen.Flannery@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Today's update. Will continue to update through the day when new information becomes available. Focus on first table in document which is new this morning.

Thanks!

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 8:01 PM

To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; Hillebrenner, Elizabeth J <Elizabeth.Hillebrenner@fda.hhs.gov>; Flannery, Ellen <Ellen.Flannery@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

News from Biosearch. See below. Their kits have (b)(4) tests per kit and their yield was increased by (b)(4); (b)(5) tests to (b)(4); (b)(5) tests. Attached updated table with these additional changes in green as well.

From Biosearch:

Attached is our invoice (b)(4); (b)(5) for the shipment of the (b)(4) kits from our initial production batch.

This batch total's (b)(4) kits.

The Fed Ex tracking # for this order is (b)(4)

(b)(4); (b)(5) early AM delivery – air bill label attached.

If you have any questions please let me know

I look forward to the feedback

Regards

Russell

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy

Sent: Friday, March 6, 2020 7:53 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>; Caccamo, Stephanie <Stephanie.Caccamo@fda.hhs.gov>; Elizabeth J Hillebrenner <Elizabeth.Hillebrenner@fda.hhs.gov> <Elizabeth.Hillebrenner@fda.hhs.gov>; Ellen Flannery <Ellen.Flannery@fda.hhs.gov> <Ellen.Flannery@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Hi,

See attached updated table. Updates are in green. IDT was able to ship (b)(4); (b)(5) tests (b)(4); (b)(5) An additional (b)(4); (b)(5) tests are available to ship on (b)(4); (b)(5)

Still awaiting confirmation from Biosearch that they have shipped kits for QC to CDC for (b)(4); (b)(5) delivery.

Best,
Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health

Office of Product Evaluation and Quality

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health

Office of Product Evaluation and Quality

CDRH | Food and Drug Administration

White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993

Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020 5:11 PM

To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

awesome

Brett P. Giroir, MD

ADM, US Public Health Service

Assistant Secretary for Health (ASH)

200 Independence Avenue, SW

Washington, DC 20201

Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 5:10 PM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

QC results came in. The new IDT lot passed QC with (b)(5); (b)(4) tests (b)(5); (b)(4) patients. I will now contact to see how many tests they could ship (b)(5); (b)(4) and will report back.

Best,
Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration

White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993

Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 5:05 PM

To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

My thoughts, I just reread the entire summary of data from the CDC, (b)(5)

(b)(5)

(b)(5)

Apologies for not being more helpful.

Best,

Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Friday, March 6, 2020 4:13 PM
To: Schuchat, Anne (CDC) <acs1@cdc.gov>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>
Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

OK high priority.
Either way we need to know. If the advice is one swab, we double test.
If that is NOT the right recommendation, no issue.
Looked like NP was far superior on the limited data we saw

Brett P. Giroir, MD
ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Sent: Friday, March 6, 2020 3:48 PM
To: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>
Subject: Re: [REDACTED] (b)(6)

Tim. You may want Steve Monroe to provide some info [REDACTED] (b)(5)
[REDACTED] (b)(5)
[REDACTED] (b)(5) I don't have data right now but believe it can be looked at.

Get [Outlook for iOS](#)

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Friday, March 6, 2020 3:23:31 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC)

<Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

I previously checked with my team and checked the CDC's package insert and it is correct. One sample per patient is sufficient. This is what is commonly done with all molecular testing not just for this virus. One test per patient is the norm.

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 9:32 AM

To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Contacted IDT by voice and they are working on getting me the numbers. They will recontact me soon.

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

Center for Devices and Radiological Health
U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692

Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020 9:02 AM

To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

300,000 tests were shipped yesterday, to be specific. Not 600,000.
Please verify and be certain

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>

Sent: Friday, March 6, 2020 8:02 AM

To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>

Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Thank you Admiral for your help with the QC testing of lots that arrive today and tomorrow at the CDC.
And more will be arriving next week.

I was a little tired last night when trying to update the math. In fact, for (b)(5); (b)(4) if we include the new lot of IDT reagents arriving at the CDC (b)(5); (b)(4) for QC testing and we include Biosearch's lot that arrives at the CDC (b)(5); (b)(4) for QC testing. The total (b)(5); (b)(4) will be (b)(5); tests (lots of (b)(5); plus (b)(5); plus (b)(5); from IDT and one lot of (b)(5); tests from Biosearch for a grand total of (b)(5); (b)(4) tests.

Best,
Tim

Timothy T. Stenzel, MD, PhD

Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

Center for Devices and Radiological Health
U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692

jennifer.campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>

Sent: Friday, March 6, 2020 7:48 AM

To: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

OK

By calculation, that would be 1.1 million since 100,000 plus 600,000 have already been shipped.

I will work with Sherri on the receipt as well as the QC timeline.

V/r
BG

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)

200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Thursday, March 5, 2020 7:00 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Lenihan, Keagan (FDA/OC) <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Dear Admiral,

I just got a new update from IDT. A new lot of kits for QC testing will arrive at CDC tomorrow by (b)(5); (b)(4). We need QC testing right away and reporting back to IDT and FDA right away. They report this lot will have (b)(5); (b)(4) reactions.

But, unfortunately, because (b)(5)

(b)(5)

I am sorry to deliver these revised lower numbers to you. However, it looks like if all lots pass QC we will have (b)(5); (b)(4) tests available to ship by the end of (b)(5); (b)(4) and (b)(5); (b)(4) total so far is reported to be (b)(5); (b)(4) tests by (b)(5); (b)(4) ThermoFisher's shipments (b)(5); (b)(4) could add to the total. I will update as soon as I get them.

(b)(5) We are grateful for the lot release testing reported (b)(5); by the CDC.

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

Center for Devices and Radiological Health

U.S. Food and Drug Administration

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy
Sent: Thursday, March 5, 2020 5:56 PM
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>
Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

And by the end of (b)(5); (b)(4) according to my industry contacts, ThermoFisher should have another (b)(5); (b)(4) to ship; IDT another (b)(5); (b)(4) tests to ship; and Biosearch will have another (b)(5); (b)(4) to ship.

Total for (b)(5); (b)(4) tests according to what the companies are telling me.

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

Center for Devices and Radiological Health
U.S. Food and Drug Administration
Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692
Jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Sent: Thursday, March 5, 2020 5:46 PM
To: Giroir, Brett (OS) <Brett.Giroir@hhs.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger,

Sherri (CDC) <sob8@cdc.gov>

Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Schwartz, Suzanne <Suzanne.Schwartz@fda.hhs.gov>; Shuren, Jeff <Jeff.Shuren@fda.hhs.gov>

Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Hi Admiral,

If the CDC immediately QC tests lots from either IDT or Biosearch upon receipt, this process will go more quickly. Not counting CDC's shipping of kits this week to PHLs, IDT shipped (b)(5); (b)(4) tests earlier this week and is shipping (b)(5); (b)(4) tests today. Biosearch has a lot of (b)(5); tests, a sampling of which will arrive at the CDC on Saturday for QC testing. If the CDC can test Saturday and give results Saturday we can potentially count those (b)(5); tests this week, though they probably wouldn't ship out until Monday.

In addition, ThermoFisher is finishing their EUA application on Monday which we will turn around quickly. They have (b)(5); tests in inventory and we gave them permission to preposition them in labs this week. I have just asked them how many tests they have shipped so far this week and how many they expect to ship yet this week. I will get those numbers to you as soon as I receive them.

Updated total this week, not counting ThermoFishers shipments which I am waiting on and counting Biosearch's tests this week: (b)(5); (b)(4)

Further, (b)(5); (b)(4)
(b)(5); (b)(4)

Feel free to call anytime. My cell is (b)(6)

Best,
Tim

Timothy T. Stenzel, MD, PhD

*Director, OHT7: Office of In Vitro Diagnostics and Radiological Health
Office of Product Evaluation and Quality*

**Center for Devices and Radiological Health
U.S. Food and Drug Administration**

Timothy.Stenzel@fda.hhs.gov

Jennifer Campbell

Administrative Assistant

OHT7: Office of *In Vitro* Diagnostics and Radiological Health
Office of Product Evaluation and Quality

CDRH | Food and Drug Administration
White Oak, Bldg. 66 3403 | 10903 New Hampshire Avenue | Silver Spring, MD 20993
Ph: 301-796-7692

jennifer.Campbell@fda.hhs.gov

Excellent customer service is important to us. Please take a moment to provide feedback regarding the customer service you have received: <https://www.research.net/s/cdrhcustomerservice?ID=1900&S=E>

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 5, 2020 5:31 PM
To: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>; Berger, Sherri (CDC) <sob8@cdc.gov>; Stenzel, Timothy <Timothy.Stenzel@fda.hhs.gov>
Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Wonderful

I am still looking for the extra 300,000 tests (to make a million).
Is that Monday?

And are we still no track for ~4 million tests next week?

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Sent: Thursday, March 5, 2020 4:19 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>; Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>; Redfield, Robert R. (CDC/OD) <olx1@cdc.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

+ Tim

From: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Sent: Thursday, March 5, 2020 4:18 PM
To: Berger, Sherri (CDC) <sob8@cdc.gov>; Lenihan, Keagan <Keagan.Lenihan@fda.hhs.gov>
Cc: Monroe, Stephan S (CDC) <stm2@cdc.gov>; Schuchat, Anne (CDC) <acs1@cdc.gov>; Redfield, Robert R (CDC) <olx1@cdc.gov>; Hahn, Stephen <SH1@fda.hhs.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!
Importance: High

The word WORLDWIDE shows up below.
Please explain – don't these go to the US only?
That is clearly the impression of national leadership

Copying Director and Commissioner on this one

Brett P. Giroir, MD

ADM, US Public Health Service
Assistant Secretary for Health (ASH)
200 Independence Avenue, SW
Washington, DC 20201
Office Phone: 202-690-7694

From: Berger, Sherri (CDC/OCOO/OD) <sob8@cdc.gov>
Sent: Thursday, March 5, 2020 4:13 PM
To: Giroir, Brett (HHS/OASH) <Brett.Giroir@hhs.gov>
Cc: Monroe, Steve (CDC/DDPHSS/OLSS/OD) <stm2@cdc.gov>; Schuchat, Anne MD (CDC/OD) <acs1@cdc.gov>
Subject: FW: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

From: Kuhnert-Tallman, Wendi (CDC/DDID/OD)
Sent: Thursday, March 5, 2020 4:13 PM
To: Terrill, Roman <rterill@idtdna.com>; Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Lindstrom, Stephen (CDC/DDID/NCIRD/DVD) <sql5@cdc.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>
Cc: Villanueva, Julie M. (CDC/DDID/NCEZID/DPEI) <jfv3@cdc.gov>; Flannery, Ellen (FDA/CDRH) <Ellen.Flannery@fda.hhs.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>; Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>
Subject: RE: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

Roman and others, I have spoken with CDC leadership. (b)(5)

(b)(5)

We would appreciate it if we could renegotiate the shared document that outlines the process for this going forward. We can set up a meeting to do this tmrw if helpful.

Thanks, wendi

Wendi Kuhnert-Tallman

Office - 404-639-3103

Mobile (b)(6)

From: Terrill, Roman (b)(6) <[idtdna.com](mailto:rterill@idtdna.com)>
Sent: Thursday, March 5, 2020 3:58 PM
To: Stenzel, Timothy (FDA/CDRH) <Timothy.Stenzel@fda.hhs.gov>; Kuhnert-Tallman, Wendi (CDC/DDID/OD) <wdk1@cdc.gov>; Lindstrom, Stephen (CDC/DDID/NCIRD/DVD) <sql5@cdc.gov>; Shuren, Jeff (FDA/CDRH) <Jeff.Shuren@fda.hhs.gov>
Cc: Villanueva, Julie M. (CDC/DDID/NCEZID/DPEI) <jfv3@cdc.gov>; Flannery, Ellen (FDA/CDRH) <Ellen.Flannery@fda.hhs.gov>; Schwartz, Suzanne (FDA/CDRH) <Suzanne.Schwartz@fda.hhs.gov>;

Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) <dbj0@cdc.gov>

Subject: Urgent 40 minute warning from IDT on ability to ship tests-3 day pause likely!!!

To my friends at FDA and CDC, and elsewhere within HHS:

Just to raise to your attention of the urgency of the time and the matter.

If IDT receives confirmation of IDT's permission to ship kits from lot '594 (which was QC'd yesterday, and that several people have suggested likely passed) **by 4:30pm Eastern (the next 40 minutes)**, IDT's team will be able to fill orders for hundreds of kits, representing thousands of tests to hundreds of institutions worldwide, for delivery and receipt on Friday (tomorrow), which ensures continuous testing capability throughout the weekend.

If does not receive said confirmation of its permission to ship kits from lot '594, then the earliest receipt of said products will be Monday morning of next week, as FedEx and UPS only do Saturday shipments by special arrangement, and we as a nation we will likely lose 3 calendar days of possible testing (FRI-SAT-SUN).

I'm not prone to the dramatic, but the circumstances warrant it.

Please advise ASAP.

Thanks,

Roman

Please be advised that this email may contain confidential information. If you are not the intended recipient, please notify us by email by replying to the sender and delete this message. The sender disclaims that the content of this email constitutes an offer to enter into, or the acceptance of, any agreement; provided that the foregoing does not invalidate the binding effect of any digital or other electronic reproduction of a manual signature that is included in any attachment.

From: Bornstein, Josh (CDC/OCOO/OSSAM)
Sent: Thu, 12 Mar 2020 16:05:17 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: EPMC - Daily Call Summary, 3/10

Ugh will fix

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>
Sent: Thursday, March 12, 2020 12:05 PM
To: Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>
Subject: RE: EPMC - Daily Call Summary, 3/10

This has your name but my title?

From: Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>
Sent: Thursday, March 12, 2020 11:49 AM
To: Daphnis, Kristy L. EOP/OMB (b)(6); DL OMB Dir Office
OMB_COVID19OPS (b)(6)
Cc: Messonnier, Nancy (CDC/DDID/NCIRD/OD) <nar5@cdc.gov>
Subject: RE: EPMC - Daily Call Summary, 3/10

And one more. Thanks!

From: Daphnis, Kristy L. EOP/OMB (b)(6)
Sent: Tuesday, March 10, 2020 7:42 PM
To: Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>; DL OMB Dir Office OMB_COVID19OPS (b)(6)
Subject: RE: EPMC - Daily Call Summary, 3/10

Received.
Thank you!

From: Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>
Sent: Tuesday, March 10, 2020 7:13 PM
To: DL OMB Dir Office OMB_COVID19OPS (b)(6)
Subject: RE: EPMC - Daily Call Summary, 3/10

Please see attached CDC access request for MAX.

Thanks,
Josh

From: Daphnis, Kristy L. EOP/OMB (b)(6)
Sent: Tuesday, March 10, 2020 5:00 PM
To: Weichert, Margaret M. EOP/OMB (b)(6); Nevins, Kristan K.

EOP/WHO (b)(6) Paz, Brooke L. EOP/WHO (b)(6)
 Connor, Cameron M. EOP/WHO (b)(6) Uldricks, Nathan R. EOP/OMB
 (b)(6) Johnson, Miles M. EOP/OMB (b)(6)
 Brown, Dustin S. EOP/OMB (b)(6) 'Irving.L.Dennis@hud.gov'
 <Irving.L.Dennis@hud.gov>; Rowell, Scott (OS/ASA) <Scott.Rowell@hhs.gov>; Slater, Bryan - ASAM
 <Slater.Bryan@DOL.gov>; Wooten, Michael E. EOP/OMB (b)(6) Kent,
 Suzette K. EOP/OMB (b)(6) 'RigasM2@opm.gov' <RigasM2@opm.gov>;
 Cutts, Matthew D. EOP/OMB <(b)(6)> Cameron, Scott J
 <scott_cameron@ios.doi.gov>; 'Mehrens, Nathan P - OSEC' <Mehrens.Nathan.P@DOL.gov>;
 'kstaley@usaid.gov' <kstaley@usaid.gov>; 'kpreskenis@doc.gov' <kpreskenis@doc.gov>; 'Morhard,
 James W. (HQ-AB000)' <james.w.morhard@nasa.gov>; 'fcrim@nsf.gov' <fcrim@nsf.gov>;
 'Charles.P.Rettig@irs.gov' <Charles.P.Rettig@irs.gov>; Brady, Will (HHS/IOS) <William.Brady@hhs.gov>;
 'Stephanie.Hall@ssa.gov' <Stephanie.Hall@ssa.gov>; 'biegunse@state.gov' <biegunse@state.gov>;
 'Justin.Muzinich@treasury.gov'; 'kate_macgregor@ios.doi.gov' <kate_macgregor@ios.doi.gov>;
 'David.Black@ssa.gov' <David.Black@ssa.gov>; 'SLC1@usda.gov' <SLC1@usda.gov>; 'kkelley@doc.gov'
 <kkelley@doc.gov>; Pizzella, Patrick - OSEC <pizzella.patrick@dol.gov>; 'edh6886@hhs.gov'
 <edh6886@hhs.gov>; MDB <Brian.D.Montgomery@hud.gov>; Boyd, Marshall T. EOP/OMB
 (b)(6) Holt, Brandon T. EOP/OMB (b)(6)
 'Bradbury, Steven (OST)' <steven.bradbury@dot.gov>; 'mark.menezes@hq.doe.gov'
 <mark.menezes@hq.doe.gov>; 'Mitchell.Zais@ed.gov' <Mitchell.Zais@ed.gov>;
 'lisa.w.hershman.civ@mail.mil' <lisa.w.hershman.civ@mail.mil>; 'BulataoBJ@state.gov'
 <BulataoBJ@state.gov>; Alles, Randolph <randolph.alles@hq.dhs.gov>; 'Patricia.Griffin@treasury.gov';
 'Justin.Muzinich@treasury.gov'; 'bglick@usaid.gov'; Warren, Peter N. EOP/OMB
 (b)(6) 'kate_macgregor@ios.doi.gov'; 'Kevin Johnson - AC'
 <kevin.d.johnson@gsa.gov>; 'SLC1@osec.usda.gov'; 'kkelley@doc.gov'; 'mitchell.zais@ed.gov';
 'emily.murphy@gsa.gov'; 'eric.hargan@hhs.gov'; 'brian.d.montgomery@hud.gov';
 'lisa.w.hershman.civ@mail.mil'; 'loyetCJ@state.gov'; 'j.morhard@nasa.gov'; 'deputysecretary@hhs.gov';
 'Berrios, Nelly (Federal)' <NBerrios@doc.gov>; 'Carla Sansalone - AC' <carla.sansalone@gsa.gov>; Dickel,
 Aman (OS/IOS) <Aman.Dickel@hhs.gov>; 'natalie.l.simms@nasa.gov'; 'lee.j.lofthus@usdoj.gov';
 'Maya.a.suero@usdoj.gov'; 'Eng, Connie' <Eng.Connzie@epa.gov>; 'kiki.adams@usda.gov';
 'noah.mitchell@ed.gov'; 'randolph.alles@hq.dhs.gov'; 'lupe.morales@hq.dhs.gov';
 'douglas.benevento@epa.gov'; 'David.Eisner@treasury.gov'; 'Samantha.Upwright@treasury.gov';
 'Paranzino, Anthony (Federal)' <AParanzino@doc.gov>; 'sfrechter@usaid.gov'; 'dfeith@usaid.gov';
 Callahan, Kenneth (HHS/IOS) <Kenneth.Callahan@hhs.gov>; 'Dale Cabaniss - OPM'
 <CabanissDV3@opm.gov>; 'Duffy, Timothy J.' <Timothy.Duffy@opm.gov>;
 'katharine_macgregor@ios.doi.gov'; Lofthus, Lee EOP <lee.j.lofthus@usdoj.gov>; 'bglick@usaid.gov';
 'emily.murphy@gsa.gov'; 'David.Eisner@treasury.gov'; 'Samantha.Upwright@treasury.gov'
 <Samantha.Upwright@treasury.gov>; Lee, Isabel H CIV OSD OCMO (USA) <isabel.h.lee.civ@mail.mil>;
 'Adams, Kiki - OSEC, Washington, DC' <kiki.adams@usda.gov>; 'noah.mitchell@ed.gov'
 <noah.mitchell@ed.gov>; 'Morales, Lupe' <lupe.morales@hq.dhs.gov>; 'douglas.benevento@epa.gov'
 <douglas.benevento@epa.gov>; 'natalie.l.simms@nasa.gov' <natalie.l.simms@nasa.gov>; Kan, Derek T.
 EOP/OMB (b)(6) 'Patricia.Griffin@treasury.gov'; Director Cabaniss
 <Director.Cabaniss@opm.gov>; 'jovita@sba.gov' <jovita@sba.gov>; 'emily.threadgill@sba.gov'
 <emily.threadgill@sba.gov>; Kinneen, Kelly A. EOP/OMB (b)(6) Reilly, Tom M.
 EOP/OMB (b)(6) 'Powers, Pamela' <Pamela.Powers@va.gov>;
 'annette.vietti-cook@nrc.gov' <annette.vietti-cook@nrc.gov>; 'Dana.Wade@hud.gov'
 <Dana.Wade@hud.gov>; Moughalian, Jen (HHS/ASFR) <Jen.Moughalian@hhs.gov>; Dickel, Aman
 (OS/IOS) <Aman.Dickel@hhs.gov>; Hittle, Taylor (HHS/ASFR) <Taylor.Hittle@hhs.gov>; Bedan, Morgan E.

EOP/WHO (b)(6); Meaney Delman, Dana M. (CDC/DDNID/NCBDDD/DBDID) <vmo0@cdc.gov>; Ward, Jacklyn A <Jacklyn.A.Ward2@hud.gov>; Corrigan, Patrick M. EOP/OMB (b)(6); 'Kristine.Svinicki@nrc.gov' <Kristine.Svinicki@nrc.gov>; 'Margaret.Doane@nrc.gov' <Margaret.Doane@nrc.gov>; 'Rafiekian, Christine (Federal)' <CRafiekian@doc.gov>; Weaver, Kiel P <kiel_weaver@ios.doi.gov>; Lim, Evelyn <Evelyn.Lim@hud.gov>; 'Kelsey.Kats@treasury.gov' <Kelsey.Kats@treasury.gov>; McCracken, Erin S. <Erin.McCracken@sba.gov>; Bird, Catherine (OS/OGC) <Catherine.Bird@hhs.gov>
 Cc: robert.borden@gsa.gov; Todd, William E (Ambassador) <ToddW@state.gov>; Bomberger, Melissa B. EOP/OMB (b)(6); Enger, Michelle A. EOP/OMB (b)(6) Abrams, Andrew D. EOP/OMB (b)(6) Lucas, Adrienne E. EOP/OMB (b)(6); Pasquantino, John C. EOP/OMB (b)(6); Sandy, Mark S. EOP/OMB (b)(6) Fairweather, Rob S. EOP/OMB (b)(6); Stewart, Milton AI - ASAM <Stewart.Milton@dol.gov>; Williams, James E - OCFO <Williams.James.E2@dol.gov>; Talbert, Kent <Kent.Talbert@ed.gov>; Kramer, John (OST) <John.Kramer@dot.gov>; allison.brigati@gsa.gov; DeputySecretary (OS/IOS) <DeputySecretary@hhs.gov>; Williams, Sarah M. <Sarah.Williams@sba.gov>; Dendas, Michael W <Michael.W.Dendas@hud.gov>; Massey, Natalie (HQ-AB000) <natalie.massey@nasa.gov>; Edgar, Troy <troy.edgar@hq.dhs.gov>; Mounts, Jeffrey C <MountsJX@state.gov>; Jeffries, Karen (HRA/OSP) <Karen.Jeffries@va.gov>; Spooner, Sarah W. EOP/OMB (b)(6); Cooper III, William S. <william.cooper@hq.doe.gov>; Bornstein, Josh (CDC/OCOO/OSSAM) <dsx2@cdc.gov>; DL OMB Dir Office OMB_COVID19OPS (b)(6); Smith, Sarah B. EOP/OMB (b)(6)
Subject: EPMC - Daily Call Summary, 3/10

Please be sure to send (and/or cc:) all OMB COVID-related Management/operations emails to

(b)(6)

Summary of EPMC Daily – 3/10/20

Situational Awareness:

- 712 confirmed/presumed. Highest number of cases still in these States: WA, NY, CA (all 100+). At least 6 States at or over ~10: MA, FL, GA, TX, OR, PA.
- CDC: enhanced reporting by States of COVID-19 cases will likely result in increased observed numbers in the coming days.
- Reminder: Please send Agency weekly reports (due yesterday) to your agency RMO/OMB Examiner. OMB has received approximately half. Kelly Kinneen (OMB) will follow up.
- VP Task Force (VP TF) is pleased that agencies are producing and posting guidance specific to their stakeholders. Agency-specific operational updates are also very helpful. The VP TF will be interested in learning about specific decision-making considerations.
- (b)(5)
- CDC: Will be issuing a Broader Community Measures guidance document – should be issued this week or next.
- CDC: Asking all Federal Agencies to coordinate with S&L public health. We encourage agencies to be in close contact with CDC, and to seek guidance from S&L public health authorities, as they have the best visibility into individual communities and community transmission considerations.

- Agencies should be postured for hyper-local responsiveness to issues (e.g., specific buildings, specific communities). GSA has been thinking about how to coordinate the GSA component of this, and is working closely with OMB – to build out reporting tools, processes, building management contacts, etc.

- (b)(5)

Grants:

- OMB issued guidance yesterday: <https://www.whitehouse.gov/wp-content/uploads/2020/03/M-20-11.pdf>
- The guidance provides more flexibility is using grants to respond to COVID situations. Guidance is meant to improve liquidity and ability to use existing funds.
- The new guidance provides flexibility to agencies in order to respond; it is not about operational impacts to grantees.
- OMB will coordinate with Agencies and GSA to produce additional grantee and contractor guidance, and to gather operational questions and issues – i.e., travel by grantees and contractors.

Buildings:

- GSA is getting a lot of building-related requests. Current recommendation for impacted buildings is to wait 24 hours before cleaning a building; GSA is working closely with CDC on issues such as the scope and timing of cleaning for impacted buildings. Volume of these requests is increasing. We need to balance risk with the judicious use of supplies. ***PLEASE let GSA know if your agency is going to telework, to help manage resources.***
- OMB is working on IT support to help manage situational awareness and operational considerations. USDS, OMB, and GSA/TTS will be providing tools in the near future.
- GSA is working on supply chain issues. For GSA owned/operated buildings - Right now, hand sanitizer should be made available in lobby and food service areas. CDC signage should be placed in bathrooms (handwashing, health tips, etc.).
- Signage should be consistent. Please use CDC materials and language for health and hygiene; FPS materials and language for security, entry, and access signage (some of which may vary locally). ***OMB will gather recommended CDC and FPS language, and will post on MAX site***
- We are putting a process in place to ensure Small and Independent agencies are alerting other agencies and OMB of operational decisions surrounding building closures and other response.

IT:

- CIO Council is looking into capacity, business continuity, cyber security, and telework tools.
- CIOs and CISOs are having a work session tomorrow, and will report back up through Agency Management chains.

Telework:

- Operative guidance on telework is the OPM guidance from March 7: <https://www.opm.gov/policy-data-oversight/covid-19/>
- If your Agency is interested in doing a telework pilot, you are able and encouraged to do that. In general, stress-tests/pilots seem to be helpful. Some lessons/issues identified to date include: disruptions to retirement processing; employees missing

laptops/chargers/other equipment. ***Please alert OMB to your lessons learned and best practices gleaned from these exercises.***

- CIO Council is looking at broad issues re: bandwidth, capacity, etc.
- GSA is starting to see supply chain effects on cell phones, laptops, etc. Recommend holding onto equipment, to ensure we have a backup supply. Use caution in both purchasing and retiring equipment.
- DOT: Looking into providing more flexibility to vulnerable employee populations (e.g., cancer, heart disease, health, etc.). If agencies are looking into this type of flexibility across all-geographies (nation- or region-wide), they should consult OMB and CDC – nothing is indicated right now for broad-spectrum measures. For local/hyper-local situations, the risk may warrant these types of flexibilities. If a S&L health department is making recommendations to cover certain vulnerable populations, that should help guide the agency's decision at the local level.
- Agency-wide telework – We are looking at trigger points based on local factors, so agencies should make circumscribed telework decisions for specific areas based on assessed risk at the local and hyper-local level – as opposed to e.g. a uniform, national agency-wide policy that applies the same telework policy to agency offices in all locales. Decisions should be made based on consultation with State and local health authorities, from a public health and epidemiological perspective and in coordination with agency headquarters. (b)(5)

(b)(5)

Customer-facing Operations:

- NRC: Parent at daycare center indicated potential exposure. NRC plans to ask parents to pick up children today. Likely newsworthy. ***GSA is tracking all 94 daycare centers – if agencies are seeing daycare issues, please let GSA know.***
- VA: Entering into restrictive visitation for nursing home facilities, including screening. Also implementing procedures at spinal cord treatment centers. VP TF is aware of these operational changes.

Comms:

- OMB spoke with FEBs this morning, reiterating that employee communications should come from Agencies (in consultation with building managers). The current situation and decision processes differ from weather – there are additional complexities. OMB is working on FEB communication protocols.

Communicating with OMB and Across PMC:

- New OMB MAX site clearinghouse – <https://go.max.gov/covid-19> will be up and running today. This site will include point-backs to relevant guidance, as well as comms materials, best practices, etc.
- New OMB email address/contact point – (b)(6)
- ***NLT COB tomorrow, 3/11/20, please send agency POCs that you would like to have access/permissions to the MAX site, using the attached excel spreadsheet. We need the following information: Name, Email address, role, and phone number. Send to the OMB Ops Email Address: (b)(6)**
- Communications will shift to MAX page and notifications, versus email. This will reduce single points of failure.

Emerging Issues:

- Trigger point issues that could prompt broader, non-localized mitigations. We are assessing wave-top issues related to: travel, transit, telework, buildings, mission/activity triage.
- Independent and small agencies: process and communications
- Streamlining and tech-enabling processes, IT, and tools
- Operational impacts on Grants and contractors, including grant and contract personnel.
- Daycare operations and considerations

Next Call:

- Check in tomorrow at noon. Please contact OMB Management Team [(b)(6)] if there are specific items you'd like to discuss or share.

Running Summary of Major Do-outs:

- Due out (3/10): Send Agency Operational Updates to OMB RMO (was due 3/9); Send Agency MAX POCs (in attached excel spreadsheet) to (b)(6) (NLT COB 3/11)
- Due out (3/9): OMB will clear and distribute TPs for agencies to use for internal comms, regarding medical/privacy, in the instance of a case being identified at a Federal employee site.
- Due out (3/8): DONE. OMB will clear and distribute TPs for agencies to use for internal comms.
- Due out (3/8): (b)(5)
- Due out (3/7): VA, IHS, DoD and others providing clinical care should send PMC group some additional information on geographical distribution, to think through how we might want to address and factor that in.
- Due outs (3/7): NASA, please share further information on metrics from your past efforts, also share sample comms. OPM, please look into resources to quickly implement/educate agencies (in addition to what's in forthcoming guidance). For now, we will share info via email.